LU92326I2 - Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) - Google Patents

Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)

Info

Publication number
LU92326I2
LU92326I2 LU92326C LU92326C LU92326I2 LU 92326 I2 LU92326 I2 LU 92326I2 LU 92326 C LU92326 C LU 92326C LU 92326 C LU92326 C LU 92326C LU 92326 I2 LU92326 I2 LU 92326I2
Authority
LU
Luxembourg
Prior art keywords
ilaris
canakinumab
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU92326C
Other languages
English (en)
Other versions
LU92326I9 (fr
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92326(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU92326I2 publication Critical patent/LU92326I2/fr
Publication of LU92326I9 publication Critical patent/LU92326I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
LU92326C 2005-10-26 2013-12-05 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) LU92326I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
PCT/US2006/041479 WO2007050607A2 (fr) 2005-10-26 2006-10-24 Nouvelle utilisation de composes il-1beta

Publications (2)

Publication Number Publication Date
LU92326I2 true LU92326I2 (fr) 2014-02-05
LU92326I9 LU92326I9 (fr) 2019-01-16

Family

ID=37806690

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92326C LU92326I2 (fr) 2005-10-26 2013-12-05 Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU00078C LUC00078I2 (fr) 2005-10-26 2018-06-11 Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU00078C LUC00078I2 (fr) 2005-10-26 2018-06-11 Traitement de la fièvre méditerranéenne familiale avec des anticorps anti IL-1 béta

Country Status (29)

Country Link
US (8) US8105587B2 (fr)
EP (5) EP2332577A1 (fr)
JP (4) JP2009513645A (fr)
KR (3) KR20170038131A (fr)
CN (2) CN101291693B (fr)
AU (1) AU2006306280B2 (fr)
BR (1) BRPI0617830B8 (fr)
CA (3) CA2963828A1 (fr)
CY (4) CY1113378T1 (fr)
DK (2) DK1940465T3 (fr)
ES (3) ES2944067T3 (fr)
HK (3) HK1121041A1 (fr)
HU (2) HUE036973T2 (fr)
IL (4) IL190545A (fr)
JO (2) JO2826B1 (fr)
LT (3) LT2848258T (fr)
LU (2) LU92326I2 (fr)
MA (1) MA29919B1 (fr)
NO (2) NO345888B1 (fr)
NZ (1) NZ567222A (fr)
PH (2) PH12013501287B1 (fr)
PL (2) PL2848258T3 (fr)
PT (2) PT2848258T (fr)
RU (2) RU2468817C2 (fr)
SI (2) SI2848258T1 (fr)
TN (1) TNSN08189A1 (fr)
TR (1) TR201802449T4 (fr)
TW (3) TWI388335B (fr)
WO (1) WO2007050607A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
EP2152308A1 (fr) * 2007-05-29 2010-02-17 Novartis Ag Nouvelles indications pour une thérapie anti-il-i-bêta
AU2012203931B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
WO2009149370A1 (fr) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Procédés pour le traitement de la polyarthrite rhumatoïde
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
EP2477647B1 (fr) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation de produits d'immunothérapie à base de levure et réponses associées
AR078650A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Anticuerpo de union a il-1 beta
KR101539684B1 (ko) * 2010-05-14 2015-07-27 애브비 인코포레이티드 Ｉｌ－１ 결합 단백질
CA2821976A1 (fr) * 2010-12-21 2012-09-13 Abbvie Inc. Immunoglobulines a double domaine variable et leurs utilisations
CA2839792A1 (fr) 2011-05-10 2012-11-15 Nestec S.A. Methodes de profilage de l'activite d'une maladie pour une prise en charge therapeutique personnalisee
WO2017153936A1 (fr) 2016-03-10 2017-09-14 Novartis Ag Arn messager chimiquement modifié
WO2018220588A1 (fr) 2017-05-31 2018-12-06 Nestec S.A. Procédés d'évaluation de la cicatrisation des muqueuses chez des patients atteints de la maladie de crohn
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2018235056A1 (fr) 2017-06-22 2018-12-27 Novartis Ag Anticorps se liant à il-1beta destinés à être utilisés dans le traitement du cancer
CA3098277A1 (fr) 2018-05-09 2019-11-14 Novartis Ag Utilisation de canakinumab
AU2019409139A1 (en) 2018-12-21 2021-06-03 Novartis Ag Use of IL-1β binding antibodies
WO2020128613A1 (fr) 2018-12-21 2020-06-25 Novartis Ag Utilisation d'anticorps de liaison à il-1bêta
JP2022516850A (ja) 2018-12-21 2022-03-03 ノバルティス アーゲー 骨髄異形成症候群の治療又は予防におけるＩＬ－１β抗体の使用
WO2020128637A1 (fr) 2018-12-21 2020-06-25 Novartis Ag UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
KR20230109107A (ko) * 2022-01-10 2023-07-19 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5350683A (en) * 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1995001997A1 (fr) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation ANTICORPS RECOMBINANTS ET HUMANISES, DIRIGES CONTRE L'IL-1β ET DESTINES AU TRAITEMENT DE TROUBLES INFLAMMATOIRES INDUITS PAR IL-1 CHEZ L'HOMME
CA2155929A1 (fr) 1993-12-14 1995-06-22 Christopher H. Evans Traitement systemique par genes des affections des tissus conjonctifs
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL144492A0 (en) 1999-02-10 2002-05-23 Interleukin Genetics Inc Therapeutics and diagnostics based on an il-1b mutation
US6566554B1 (en) * 1999-07-16 2003-05-20 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Aminobenzophenones as inhibitors of IL-1β and TNF-α
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
WO2001087328A2 (fr) * 2000-05-12 2001-11-22 Immunex Corporation Inhibiteurs d"interleukine 1 dans le traitement de maladies
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
PE20020544A1 (es) 2000-11-07 2002-07-30 Novartis Ag Derivados de indolilmaleimida
EP1423432A4 (fr) * 2001-07-26 2006-01-11 Lilly Co Eli Anticorps vis-a-vis de l'interleukine 1 beta (il-1beta)
AU2002324625B2 (en) * 2001-08-07 2008-05-08 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
EP1459435B1 (fr) 2001-12-01 2012-05-02 Iskra Wind Turbines Ltd. Generateur de courant alternatif synchrone dote d'un mecanisme de freinage
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
EP1478648B1 (fr) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Composes contenant du phosphore et utilisations associees
CA2474645C (fr) 2002-02-01 2011-08-09 Omeros Corporation Compositions et methodes d'inhibition systemique de la degradation du cartilage
AU2003216227A1 (en) * 2002-02-11 2003-09-04 Arkion Life Sciences Llc Purified cytokine inhibitory factor
TW200918046A (en) 2002-04-03 2009-05-01 Novartis Ag Indolylmaleimide derivatives
BR0317099A (pt) 2002-12-09 2005-10-25 Boardd Of Regents Of The Unive Método in vitro para inibir a função e/ou proliferação de uma janus tirosina quinase 3, método de teste in vitro para auxiliar na identificação de substâncias que são úteis como imunossupressores terapêuticos, método in vitro para auxiliar na identificação de um novo medicamento imunossupressor, método in vitro para inibir a função e/ou proliferação de uma célula expressando a janus tirosina quinase 3, uso de pelo menos um composto, composto quìmico isolado ou purificado e composição farmacêutica
WO2004067568A2 (fr) * 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Antagonistes de l'il-1 beta humaine
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2005047906A1 (fr) 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methodes de controle de l'il-18
ZA200602666B (en) 2004-01-12 2007-09-26 Cytopia Res Pty Ltd Selective kinase inhibitors
ES2523147T3 (es) * 2004-02-26 2014-11-21 Baylor Research Institute Composiciones y métodos para el tratamiento sistémico de la artritis
CN1980658A (zh) * 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
MXPA06014126A (es) * 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
US8003779B2 (en) 2005-01-20 2011-08-23 University Of Rochester Compositions and methods for studying and treating inflammatory diseases and disorders
EP1866428A2 (fr) 2005-03-18 2007-12-19 Microbia, Inc. Production de caroténoïdes dans de la levure ou des champignons oléagineux
ES2827247T3 (es) 2005-06-21 2021-05-20 Xoma Us Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
PL2848258T3 (pl) * 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta

Also Published As

Publication number Publication date
CN101291693A (zh) 2008-10-22
RU2468817C2 (ru) 2012-12-10
CA2626214C (fr) 2016-06-21
JP6061747B2 (ja) 2017-01-18
PH12013501287A1 (en) 2016-02-01
CY2018018I2 (el) 2018-12-12
PL1940465T3 (pl) 2013-01-31
PT2848258T (pt) 2018-03-20
KR20080059598A (ko) 2008-06-30
NO20082344L (no) 2008-07-22
US20180201674A1 (en) 2018-07-19
EP3332807A2 (fr) 2018-06-13
JO2826B1 (en) 2014-09-15
RU2571563C2 (ru) 2015-12-20
US20210147533A1 (en) 2021-05-20
IL245387A0 (en) 2016-06-30
EP2848258B1 (fr) 2017-12-13
ES2389110T3 (es) 2012-10-23
TNSN08189A1 (en) 2009-10-30
PH12020500559A1 (en) 2021-06-14
MA29919B1 (fr) 2008-11-03
ES2944067T3 (es) 2023-06-19
BRPI0617830A2 (pt) 2011-08-09
PL2848258T3 (pl) 2018-06-29
TW201617097A (zh) 2016-05-16
JP2013166757A (ja) 2013-08-29
WO2007050607A3 (fr) 2007-06-28
US20170218063A1 (en) 2017-08-03
HK1121041A1 (en) 2009-04-17
TR201802449T4 (tr) 2018-03-21
TWI626056B (zh) 2018-06-11
CY2018018I1 (el) 2018-12-12
NO20200810A1 (no) 2008-07-22
AU2006306280B2 (en) 2010-06-17
LTC1940465I2 (lt) 2017-12-11
CA2898369C (fr) 2017-06-20
LTPA2018506I1 (lt) 2018-06-25
CN101291693B (zh) 2012-10-03
EP1940465A2 (fr) 2008-07-09
CN102861332A (zh) 2013-01-09
IL190545A (en) 2016-09-29
US20120039910A1 (en) 2012-02-16
BRPI0617830B8 (pt) 2021-05-25
JOP20140120B1 (ar) 2021-08-17
DK1940465T3 (da) 2012-10-22
US8409576B2 (en) 2013-04-02
JP2017206552A (ja) 2017-11-24
WO2007050607A2 (fr) 2007-05-03
RU2008120625A (ru) 2010-01-20
EP3332807B1 (fr) 2023-02-22
LT2848258T (lt) 2018-02-26
IL277406A (en) 2020-11-30
EP1940465B1 (fr) 2012-08-01
HK1204767A1 (en) 2015-12-04
TWI537003B (zh) 2016-06-11
HUS1800025I1 (hu) 2018-07-30
CA2626214A1 (fr) 2007-05-03
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
CY2013046I1 (el) 2015-11-04
JP6286403B2 (ja) 2018-02-28
TW200803898A (en) 2008-01-16
BRPI0617830B1 (pt) 2020-10-20
TW201302220A (zh) 2013-01-16
EP3332807A3 (fr) 2018-06-20
EP4218815A2 (fr) 2023-08-02
EP4218815A3 (fr) 2024-03-27
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
LU92326I9 (fr) 2019-01-16
HUE036973T2 (hu) 2018-08-28
US20130171167A1 (en) 2013-07-04
TWI388335B (zh) 2013-03-11
JP2009513645A (ja) 2009-04-02
KR101518064B1 (ko) 2015-05-06
LTC2848258I2 (lt) 2019-08-12
CA2963828A1 (fr) 2007-05-03
EP2848258A1 (fr) 2015-03-18
PT1940465E (pt) 2012-10-03
US8105587B2 (en) 2012-01-31
CY1120018T1 (el) 2018-12-12
IL245387B (en) 2019-09-26
DK2848258T3 (en) 2018-03-19
RU2012133522A (ru) 2014-02-20
CA2898369A1 (fr) 2007-05-03
SI1940465T1 (sl) 2012-10-30
EP2332577A1 (fr) 2011-06-15
IL190545A0 (en) 2008-11-03
PH12013501287B1 (en) 2016-02-01
ES2662420T3 (es) 2018-04-06
CY2013046I2 (el) 2015-11-04
IL258983B (en) 2020-10-29
AU2006306280A1 (en) 2007-05-03
HK1252316A1 (zh) 2019-05-24
SI2848258T1 (en) 2018-03-30
US20080286266A1 (en) 2008-11-20
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
IL258983A (en) 2018-06-28
KR101749388B1 (ko) 2017-06-20
NO345888B1 (no) 2021-09-27
US20150322148A1 (en) 2015-11-12
KR20150013834A (ko) 2015-02-05
JP2016020377A (ja) 2016-02-04
CY1113378T1 (el) 2015-11-04

Similar Documents

Publication Publication Date Title
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU93093I2 (fr) Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU93096I2 (fr) Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LUC00127I1 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU92336I2 (fr) Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LTPA2016032I1 (lt) Hipoglikeminių agentų skyrimo būdai
CY2014011I1 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
DE60307677D1 (de) Dispergierbare pharmazeutische zusammensetzungen
DK1750683T3 (da) Formuleringer med langvarig frigivelse
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
ATE337793T1 (de) Dispergierbare pharmazeutische zusammensetzung eines entzündungshemmers
IS7872A (is) Pýrrólópýrimidín afleiður
BRPI0511900A (pt) composições farmacêuticas
DK1725218T3 (da) Farmaceutisk sammensætning omfattende pimobendan
DE602005008726D1 (de) Verwendet
LU92634I2 (fr) Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)
DK1587478T3 (da) Farmaceutisk sammensætning
NL1024677A1 (nl) Therapeutische prolinederivaten.